Accys Technologies - Science and technology company focused on 'sustainability' via the development and commercialisation of a range of transformational technologies based upon the acetylation of solid wood and wood elements.
Amyris Biotechnologies - is one of the companies driving the change from chemistry to biology dominance, via the emerging science of synthetic biology. Amyris technology makes it possible to alter the metabolic pathways of microorganisms such as yeasts, creating living factories that produce molecules with practical applications. While reading, writing, and analyzing the DNA of microbes once took years, Amyris can now reprogram microorganisms and test our ability to produce desired molecules in days to weeks. Amyris proprietary technology transforms plant-based feedstocks, such as sugarcane, into 50,000 different isoprenoids –molecules used in a wide variety of energy, pharmaceutical, and chemical applications.
KurzveilAI.net - KurzweilAI.net features the big thoughts of today's big thinkers examining the confluence of accelerating revolutions that are shaping our future world, and the inside story on new technological and social realities from the pioneers actively working in these arenas.
Numenta - is creating a new type of computing technology modeled on the structure and operation of the neocortex called Hierarchical Temporal Memory, or HTM, with the potential to solve many difficult problems in machine learning, inference, and prediction, and applicable to a broad class of problems from machine vision, to fraud detection, to semantic analysis of text. It is a technology tools and platform provider rather than an application developer.
Biovex - Privately held biotechnology company based in Woburn (MA), where it also has an operational launch grade manufacturing facility, is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.
Ogmento - creates and publishes mobile AR (augmented reality) experiences, made in collaboration with the best and brightest AR makers in the world.
Nano Retina - is developing an ultra small, easy to implant, artificial retina designed to restore sight.
Ysios Capital Partners, S.G.E.C.R, S.A. - Gestora de entidades de capital de riesgo independiente registrada ante la CNMV, con oficina principal en Barcelona, invierte en proyectos de innovación en el ámbito de la salud (Life Science & Healthcare). Su primer Fondo de Capital Riesgo, Ysios BioFund I, dispone de 69 MM€. Según nota de prensa del 16 nov 2009, ha invertido unos 47 MM€ en Biovex; esto es coherente con lo anunciado el 10 nov por la propia Biovex. También ha tomado participación en Cellerix y Endosense.
DARPA - Defense Advanced Research Projectys Agency - DARPA’s self-declared mission is to maintain the technological superiority of the U.S. military and prevent technological surprise from harming our national security by sponsoring revolutionary, high-payoff research bridging the gap between fundamental discoveries and their military use.
Wake Forest Institute for Regenerative Medicine - Has all the components in place to allow basic and clinical research to work in concert. With the goal of speeding the process of discovery, the lab is designed for collaboration -scientists in the fields of biomedical and chemical engineering, cell and molecular biology, biochemistry, physiology, materials science, nanotechnology, genomics, proteomics, drug delivery, surgery and medicine work side by side. And, has invested in a good manufacturing process facility -basically a biotechnology workshop- that allows it to engineer tissues and organs that meet the strict requirements of the U.S. Food and Drug Administration. This environment facilitates the transfer of technologies from the laboratory to the patients who need them. its current research focuses on a wide range of engineered tissues with the aim of making a lasting impact on conditions ranging from diabetes to heart disease. In addition, they are working to apply the science of regenerative medicine to battlefield injuries and are working to help solve the shortage of donated organs available for transplant. As a result of its preliminary successes, tissue engineering and cellular therapy programs now span multiple organ systems.